Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥18 years of age~* Histologic confirmation of renal cell carcinoma (RCC) with clear-cell component~* Advanced/metastatic RCC~* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Received 1 or 2 prior anti-angiogenic therapy regimens in advanced or metastatic setting~* No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting, and evidence of progression on or after last treatment regimen received and within 6 months of enrollment~* Karnofsky Performance Score ≥70%~Exclusion Criteria:~* Any Central Nervous System (CNS) metastases or history of CNS metastases~* Prior therapy with an Mammalian target of rapamycin (mTOR) inhibitor~* Any active known or suspected autoimmune disease~* Uncontrolled adrenal insufficiency~* Active chronic liver disease~* Prior malignancy active within past 3 years, except for locally curable cancers~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Arm 2: Everolimus (Type: ACTIVE_COMPARATOR): Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).